You know Serum Institute of India for vaccines. But they’re also a major force in antibodies — especially biosimilars. Their partnership with Roche to produce affordable trastuzumab (Herceptin) has saved thousands of breast cancer patients in India and Africa. The India antibodies market research shows that Serum’s entry into the antibody space has forced prices down by 50‑70%, making treatment accessible to the lower middle class.

But it’s not just about price. Serum has also invested in advanced manufacturing — single‑use bioreactors, continuous processing — that reduces contamination risk and improves yield. The India antibodies market trends highlight that subcutaneous administration is the fastest‑growing route, because Serum and others are developing high‑concentration formulations that patients can inject at home.

What’s next? Serum is eyeing the biosimilar market for immunology drugs (Humira, Stelara) and next‑gen antibodies for diabetes and obesity. If they succeed, they could disrupt the global market.

For patients: affordable antibodies are no longer a dream. For competitors: watch out. The Serum effect is real.